

2021- 2025 Publications

PPD™ CorEvitas™ Clinical Registries

Publication type

Manuscripts	3
Atopic Dermatitis	3
CERTAIN	3
Inflammatory Bowel Disease	3
Multiple registries	3
NMOSD	3
PsA/SpA	4
Psoriasis	4
Rheumatoid Arthritis	7
RA Japan	10

Abstracts & Presentations	10
Alopecia Areata	10
Atopic Dermatitis	10
CERTAIN	12
Inflammatory Bowel Disease	12
Multiple Sclerosis	13
Multiple registries	13
NMOSD	13
PsA/SpA	13
Psoriasis	15
Rheumatoid Arthritis	21
RA Japan	24
Reviews & Methods	24

How to navigate around the list



Returns to contents page



Go to next page



Go to previous page

Click publication type/title to take you to that page

Publication type	
Manuscripts	3
Atopic Dermatitis	3
CERTAIN	3
Inflammatory Bowel Disease	3
Multiple registries	3
NMOSD	3
PsA/SpA	4
Psoriasis	4
Rheumatoid Arthritis	7
RA Japan	10
Abstracts & Presentations	10
Alopecia Areata	10
Atopic Dermatitis	10
CERTAIN	12
Inflammatory Bowel Disease	12
Multiple Sclerosis	13
Multiple registries	13
NMOSD	13
PsA/SpA	13
Psoriasis	15
Rheumatoid Arthritis	21
RA Japan	24
Reviews & Methods	24

Manuscripts

Atopic Dermatitis

Silverberg JI, Pierce E, Feely M, Atwater AR, Schrader A, Jones R, Dave SS, Simpson E. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry. *J Dermatolog Treat*. 2023;34(1):2246601.

Silverberg JI, Shi VY, Alexis A, Pierce E, Cronin A, McLean RR, Roberts-Toler C, Rueda MJ, Atwater AR, Simpson E. Racial and ethnic differences in sociodemographic, clinical, and treatment characteristics among patients with atopic dermatitis in the United States and Canada: real-world data from the CorEvitas Atopic Dermatitis Registry. *Dermatol Ther (Heidelb)*. 2023;13(9):2045-2061.

Simpson E, Lio P, Pierce E, Cronin A, McLean RR, Eckmann T, Reck Atwater A, Dawson Z, Silverberg JI. Impact of atopic dermatitis lesion locations and extent on patient burden: a real-world study. *JEADV Clinical Practice*. 2024;3(4):939-1341.

Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. *JAAD International*. 2024;15:127-30.

Silverberg JI, Stein Gold L, Desai S, Golant A, DiRuggiero D, Fenske C, Li A, Dawson Z, Munoz Maldonado Y, Ho K, Callahan K, Simpson EL. Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from the CorEvitas Atopic Dermatitis Registry. *J Dermatological Treatment*. 2024;35(1):2396382.

Simpson EL, Stein Gold L, Desai SR, Golant AK, DiRuggiero D, Fenske C, Munoz Maldonado Y, Li AH, Dawson Z, Ho K, Callahan K, Gallo G, Silverberg JI. Characteristics of adult patients with atopic dermatitis initiating biologics and Janus kinase inhibitors in the CorEvitas Atopic Dermatitis Registry. *JEADV Clinical Practice*. 2026;5(1):101-16. [epub 2025].

CERTAIN

Curtis JR, Kremer JM, Reed G, John AK, Pappas DA. TNFi cycling versus changing mechanism of action in TNFi-experienced patients: result of the Corrona CERTAIN comparative effectiveness study. *ACR Open Rheumatol*. 2022;4(1):65-73.

Inflammatory Bowel Disease

Cross R, Sauk J, Zhuo J, Harrison R, Kerti S, Emeanuru K, O'Brien J, Ahmad H, Sreih A, Nguyen J, Horst S, Hudesman D. Poor patient-reported outcomes and impaired work productivity in patients with inflammatory bowel disease in remission. *Gastro Hep Advances*. 2022;1:927-935.

Fan Y, Delgado-Aros S, Valdecantos WC, Janak JC, Moore PC, Crabtree MM, Stidham RW. Characteristics of patients with Crohn's disease with or without perianal fistulae in the CorEvitas Inflammatory Bowel Disease Registry. *Dig Dis Sci*. 2023;68(1):214-22.

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK. Change in urgency status among ulcerative colitis patients: understanding a potential unmet patient need from the CorEvitas Inflammatory Bowel Disease Registry. *Gastro Hep Advances*. 2023;2(6):799-809.

Feagins LA, Moore P, Crabtree MM, Eliot M, Lemay CA, Loughlin AM, Gaidos JKJ. Impact of fatigue on work productivity, activity impairment, and healthcare resource utilization in inflammatory bowel disease. *Crohns Colitis 360*. 2024;7(1):otae073.

Multiple registries

Janak JC, Loughlin AM, Moore PC, Lemay CA, Mease PJ, Lebwohl M, Korzenik JR, Cross RK, Hudesman D. The burden of work productivity and activity impairment in patients with psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. *Dig Dis Sci*. 2024;69(8):2784-95.

NMOSD

Bennett JL, Middaugh N, Yeaman MR, Smith TJ, Behne MK, Crabtree M, McLean RR, Pappas DA, Levy M. SPHERES: innovative registry addressing the new era of neuromyelitis optica spectrum disorders (NMOSD) therapy. *Mult Scler Relat Disord*. 2026;107:106940. [epub 2025].

PsA/SpA

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Zhao RS, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JA. Improvements in patient-reported outcomes through six months of guselkumab treatment in patients with active psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. *ACR Open Rheumatol.* 2024;6(5):304-11.

Mease PJ, Reed G, Ogdie A, Pappas DA, Kremer JM. Prevalence of fibromyalgia and widespread pain in psoriatic arthritis: association with disease severity assessment in a large US registry. *Arthritis Care & Research.* 2024;76(9):1313-21.

Mease PJ, Young P, Fallon L, Mundayat R, Dina O, Blachley T, Middaugh N, Ogdie A. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. *Rheumatol Ther.* 2024;11(2):313-29.

Mease PJ, Nowak M, Choi J, Lehman T, Sreih A, Ho K, Middaugh N, Ogdie A. Delay of treatment with disease-modifying antirheumatic drugs in psoriatic arthritis: the CorEvitas PsA/SpA Registry. *ACR Open Rheumatol.* 2025;7(6):e70019.

Ogdie A, Middaugh N, Blachley T, Bourgeois Y, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ. Effectiveness of tofacitinib in patients with psoriatic arthritis initiating monotherapy versus combination therapy: results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. *Rheumatol Ther.* 2026;13(1):195-212. [epub 2025].

Psoriasis

Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M. Characterization of patients with psoriasis in challenging-to-treat body areas in the Corrona Psoriasis Registry. *Dermatology* 2021;237(1):46-55.

Enos CW, O'Connell KA, Harrison RW, McLean RR, Dube B, Van Voorhees AS. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. *JID Innovations.* 2021;1:100025.

Gottlieb AB, Merola JF, Cirulli J, Williams CC, Linowski GJ, Paris M, Litman HJ, Guo N, Emeanuru K, McLean RR, Cronin A, Strober B. Characteristics of patients with psoriasis treated with apremilast in the Corrona Psoriasis Registry. *Dermatol Ther (Heidelb).* 2021;11(1):253-63.

Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Gallo G, Strober B, Van Voorhees A. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry. *Dermatol Ther.* 2021;34(2):e14808.

Shahriari N, Mattessich S, Lin TC, Litman HJ, McLean RR, Dube B, Shahriari M. Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients. *J Comp Eff Res.* 2021;10(16):1215-24.

Shahriari N, Lin TC, Litman HJ, Dube B, McLean RR, Shahriari M. Characterization of real-world psoriasis patients with and without a history of depression: the Corrona Psoriasis Registry. *J Am Acad Dermatol.* 2021;84(5):1444-47.

Strober B, Kotowsky N, Medeiros R, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK, Lebwohl M. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona Registry dermatologists. *Dermatol Ther (Heidelb).* 2021;11(2):529-41.

Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. *J Dermatolog Treat.* 2021;32(3):302-9.

Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. *J Dermatolog Treat.* 2021;32(8):907-15.

Wu JJ, Kearns DG, Lin TC, Chat VS, Litman HJ, Dube B, McLean RR. Characterization of non-responders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona Psoriasis Registry. *J Eur Acad Dermatol Venereol.* 2021;35(8):e531-e527.

Wu JJ, Schrader A, McLean RR, Valdecantos W, Etzel C, Singh R. Improvement in body surface area is associated with better quality of life among patients with psoriasis in the Corrona Psoriasis Registry. *J Am Acad Dermatol.* 2021;84(6):1715-17.

Wu AJ, Harrison RW, Zhu B, Goldblum OM, Malatestinic WN, Burge R, Murage MJ. Understanding characteristics of patients newly initiating ixekizumab: Findings from the Corrona Psoriasis Registry. *J Comp Eff Res.* 2021;10(2):157-67.

Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Effectiveness of guselkumab therapy among patients with plaque psoriasis with baseline IGA score ≥ 2 in the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2023;13(2):487-504.

Enos CW, Ramos V, McLean RR, Lin TC, Foster N, Dube B, Van Voorhees AS. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity. *J Dermatolog Treat*. 2022;33(7):2975-82.

Enos CW, Yi JZ, McLean RR, Sima AP, Kohl EA, Eckmann T, Van Voorhees AS. Similar response to biologic therapy across racial and ethnic groups among patients with psoriasis enrolled in the CorEvitas Psoriasis Registry. *J Am Acad Dermatol*. 2022;87(5):1087-9.

Enos CW, Ramos V, McLean RR, Lin TC, Foster N, Dube B, Van Voorhees AS. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in the CorEvitas Psoriasis Registry. *J Am Acad Dermatol*. 2022;86(1):68-76.

Enos CW, O'Connell K, Harrison RW, McLean RR, Dube B, Van Voorhees AS. Regional variation in DLQI 0/1 within the CorEvitas Psoriasis Registry 6 months following biologic initiation. *SKIN The Journal of Cutaneous Medicine*. 2022;6(1):41-3.

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu Baojin, Malatestinic WN, Atiya B, Murage MJ, Burge RT. Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2022;12(12):2797-2815.

Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE, Zhuo J, Patel V, Mease PJ. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. *J Am Acad Dermatol*. 2022;87(6):1303-11.

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. *J Dermatolog Treat*. 2022;33(8):3178-87.

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Utilization trends and impact of secukinumab treatment on clinical outcomes in biologic-naive patients with psoriasis in a US real-world setting. *Dermatol Ther (Heidelb)*. 2022;12(6):1351-65.

Walsh JA, Duffin KC, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, UY J, McLean RR, Malley W, Cronin A, Merola JF. Demographics, disease characteristics, and patient-reported outcomes among patients with psoriasis who initiated guselkumab in CorEvitas' Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2022;12(1):97-119.

Lebwohl MG, Medeiros RA, Mackey RH, Valdecantos WC, Brodovicz KG, Lertratanakul A, Strober B. Palmoplantar pustulosis has a greater disease burden than plaque psoriasis: real-world evidence from the CorEvitas Psoriasis Registry. *J Psoriasis and Psoriatic Arthritis*. 2023;8(2):56-65.

Yu C, Wang G, Burge RT, Ye E, Dou G, Li J, Harrison RW, McLean RR, Kerti SJ, Bagel J. Outcomes of biologic use in Asian compared with non-Hispanic White adult psoriasis patients from the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2023;13(1):187-206.

Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. The effectiveness of guselkumab by BMI category among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. *Adv Ther*. 2023;40(5):2493-2508.

Enos CW, Ramos VL, McLean RR, Lin TC, Dube B, Van Voorhees AS. Proportions of biologic discontinuation among psoriasis patients with metabolic comorbidities. *J Psoriasis and Psoriatic Arthritis*. 2023;8(1):7-10.

Jin JQ, Cronin A, Roberts-Toler C, Yeroushalmi S, Haderl E, Spencer RK, Elhage KG, Gondo G, Wallace EB, Reddy SM, Han G, Kaffenberger J, Davis MS, Hakimi M, Scher JU, Armstrong AW, Bhutani T, McLean RR, Liao W. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: a 2015-2022 prospective cohort analysis of the CorEvitas Psoriasis Registry. *J Am Acad Dermatol*. 2023;89(5):974-83.

Strober B, Ferris K, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. *J Am Acad Dermatol*. 2024;90(1):p82-90.

McLean RR, Sima AP, Beaty S, Low R, Spitzer RL, Stark JL, Lesser E, Lee E, Armstrong A. Skin clearance is associated with reduced treatment failure in patients with psoriasis: real-world evidence from the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2023;13(11):2739-51.

Armstrong AW, Fitzgerald TP, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Real-world effectiveness of 9-12 months of guselkumab therapy among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2023;13(2):629-640.

McLean RR, Sima AP, Beaty S, Jones EA, Low R, McClung L, Spitzer RL, Stark J, Armstrong A. Durability of near-complete skin clearance in patients with psoriasis using systemic biologic therapies: real-world evidence from the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2023;13(11):2753-68.

Gulliver WP, See K, Zhu B, Konicek BW, Harrison RW, McLean RR, Kerti SJ, Burge RT, Leonardi CL. Development of psoriasis assessment tools among patients in the CorEvitas Psoriasis Registry. *Journal of Psoriasis and Psoriatic Arthritis*. 2023;8(2):74-82.

Strober B, Callis Duffin K, Lebwohl M, Sima A, Janak J, Patel M, Photowala H, Garg V, Bagel J. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: An analysis from the CorEvitas Psoriasis Registry. *J Dermatological Treatment*. 2024;35(1):2287401.

Enos CW, Yi JZ, Ormaza Vera A, McLean RR, Sima AP, Eckmann T, Van Voorhees AS. Racial/ethnic differences in biologic treatment patterns among psoriasis patients in the CorEvitas Psoriasis Registry. *J Am Acad Dermatol*. 2024;91(4):717-719.

Lebwohl M, Strober B, Schrader A, Li AH, Eckmann T, Zhu B, Malatestinic WN, Birt J, Feely M, Blauvelt A. Six-month real-world study to assess the effectiveness of ixekizumab after switching from IL-23 inhibitors and other biologic therapies: the CorEvitas Psoriasis Registry. *Drugs - Real World Outcomes*. 2024;11(3):451-464.

Blauvelt A, McLean RR, Beaty SW, Sima AP, Low R, Strong JL, McClung L, Bagel J. Impact of disease burden of patients with psoriasis on biologic therapy switching: real-world evidence from the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2024;14(10):2787-2804.

Mease PJ, Blauvelt A, Jones E, Sima AP, Beaty SW, Low R, Gomez B, Gurrola M, Lebwohl MG. Impact of disease factors of patients with psoriasis and psoriatic arthritis on biologic therapy switching: real-world evidence from the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2024;14(10):2805-25.

Strober BE, Janak JC, Fitzgerald T, Marchese M, Teneralli RE, Rowland K, Choi O, Chan D, Lesser E, Cameron M, Lebwohl M. Two-year treatment persistence of guselkumab vs. other biologics in plaque psoriasis patients. *J Drugs Dermatol*. 2025;24(8):762-8.

Grant C, Perez-Chada LM, Harrison RW, McLean RR, Dube B, Crabtree MM, Gottlieb AB, Merola JF. Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry. *Clin Exp Dermatol*. 2024;49(9):1016-23.

Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Criteria for identifying candidates for systemic psoriasis treatment in the real world: application of the International Psoriasis Council Guidelines in patients in North America. *J Psoriasis Psoriatic Arthritis*. 2024;10(1):22-27.

Patel V, Park SH, Zhong Y, Sima AP, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. The association between patient-reported disease burden and treatment switching in patients with plaque psoriasis treated with nonbiologic systemic therapy. *Psoriasis (Auckl)*. 2024;14:167-174

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council classification. *Dermatol Ther (Heidelb)*. 2025;15(9):2409-21.

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima AP, Li AH, Kang HJ, Main SI, Khattri S, Stein Gold L. Patient-reported outcomes by baseline body surface area involvement among individuals initiating biologic therapy: results from the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2025;15(8):2117-30.

Strober BE, Janak JC, Fitzgerald T, Marchese M, Teneralli RE, Rowland K, Choi O, Chan D, Lesser E, Cameron M, Lebwohl M. Two-year treatment persistence of guselkumab vs other biologics in plaque psoriasis patients. *J Drugs Dermatol*. 2025;24(8):762-8.

Rheumatoid Arthritis

Cohen S, Wells AF, Curtis JR, Dhar R, Mellors T, Zhang L, Withers JB, Jones A, Ghiassian SD, Wang M, Connolly-Strong E, Rapisardo S, Gatalica Z, Pappas DA, Kremer JM, Saleh A, Akmaev VR. A molecular signature response classifier to predict inadequate response to tumor necrosis factor- α inhibitors: the NETWORK-004 Prospective Observational Study. *Rheumatol Ther*. 2021;8(3):1159-76.

Cohen SB, Greenberg JD, Harnett J, Madsen A, Smith TW, Gruben D, Zhang R, Lukic T, Woolcott J, Dandreo KJ, Litman HJ, Blachley T, Lenihan A, Chen C, Rivas JL, Dougados M. Real-world evidence to contextualize clinical trial results and inform regulatory decisions: tofacitinib modified-release once-daily vs immediate-release twice-daily for rheumatoid arthritis. *Adv Ther*. 2021;38(1):226-48.

Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-world outcomes associated with methotrexate, sulfasalazine, and hydroxychloroquine triple therapy versus tumor necrosis factor inhibitor/methotrexate combination therapy in patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken)*. 2021;73(8):1114-24.

Harrold LR, Bryson J, Lehman T, Zhuo J, Gao S, Han X, Schrader A, Rebello S, Pappas DA, Somers T, Kremer JM. Association between baseline anti-cyclic citrullinated peptide antibodies and 6-month clinical response following abatacept or TNF inhibitor treatment: a real-world analysis of biologic-experienced patients with RA. *Rheumatol Ther*. 2021;8(2):937-53.

Johansson FD, Collins JE, Yau V, Guan H, Kim SC, Losina E, Sontag D, Stratton J, Trinh H, Greenberg J, Solomon DH. Predicting response to tocilizumab monotherapy in rheumatoid arthritis: a real-world data analysis using machine learning. *J Rheumatol*. 2021;48(9):1364-70.

Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold L, Feathers VL, Shadick N, Weinblatt ME, Reed G. The Clinical Disease Activity Index (CDAI) and the Routine Assessment of Patient Index Data3 (RAPID3) for achievement of treatment strategies. *J Rheumatol*. 2021;48(12):1776-83.

Kremer JM, Reed G, Pappas DA, Kane K, Feathers VL, Weinblatt ME, Shadick N, Greenberg J, Harrold LR. Dr. Kremer et al. reply. *J Rheumatol*. 2022;49(3):338-9.

Kremer JM, Bingham CO, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ,

Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. *ACR Open Rheumatol*. 2021;3(3):173-84.

Mease PJ, Stryker S, Liu M, Salim B, Rebello S, Gharaibeh M, Collier DH. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. *Arthritis Res Ther*. 2021;23(1):236.

Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration- dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naïve patients with rheumatoid arthritis. *Ann Rheum Dis*. 2021;80(12):1522-9.

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Puneekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. *Ann Rheum Dis*. 2021;80(1):96-102.

Pappas DA, Litman HJ, Lesperance T, Kricorian G, Karis E, Rebello S, Hua W, Accortt NA, Stryker S. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of Corrona registry data. *Rheumatol Int*. 2021;41(2):381-90.

Pappas D, Blachley T, Best JH, Zlotnick S, Reiss W, Emeanuru K, Kremer JM. Durability of response to tocilizumab therapy in rheumatoid arthritis: data from the US-based Corrona Rheumatoid Arthritis Registry. *Rheumatol Ther*. 2021;8(1):467-81.

Pappas DA, Brittle C, Mossell JE III, Withers JB, Lim-Harashima J, Kremer JM. Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. *Rheumatol Int*. 2021;41(3):585-93.

Petro AD, Dougherty J, England BR, Sayles H, Duryee MJ, Hunter CD, Kremer JM, Pappas DA, Robinson WH, Curtis JR, Thiele GM, Mikuls TR. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. *Int Immunopharmacol*. 2021;91:107260.

Solomon DH, Xu C, Collins J, Kim SC, Losina E, Yau V, Johansson FD. The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. *Arthritis Res Ther.* 2021;23(1):26.

Winthrop KL, Citera G, Gold D, Henrohn D, Connell CA, Shapiro AB, Shi H, Onofrei AM, Pappas DA, Schulze-Koops H. Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. *Ann Rheum Dis.* 2021;80(1):134-6.

Baker JF, Reed G, Kremer J. Weight fluctuation and the risk of cardiovascular events in patients with rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2022;74(2):229-35.

Baker JF, Reed G, Poudel DR, Harrold LR, Kremer JM. Obesity and response to advanced therapies in rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2022;74(11):1909-16.

Hansen KE, Mortezaei M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. *Ther Adv Musculoskelet Dis.* 2022;14:1-13.

Harrold LR, Connolly SE, Wittstock K, Zhuo J, Kelly S, Lehman T, Shan Y, Rebello S, Guo L, Khaychuk V. Baseline anti-citrullinated protein antibody status and response to abatacept or non-TNFi biologic/targeted-synthetic DMARDs: US observational study of patients with RA. *Rheumatol Ther.* 2022;9(2):465-80.

Padula AS, Pappas DA, Fiore A, Blachley TS, Ford K, Emeanuru K, Kremer JM. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. *Arthritis Res Ther.* 2022;24(1):276.

Pappas DA, Brittle C, Concoff A, Holman AJ, Takasugi D, Kremer JM. Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey. *Rheumatol Int.* 2022;42(9):1555-64.

Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E, Solomon DH. Examining the potential direct cardiovascular benefit of tumor-necrosis factor inhibitor in rheumatoid arthritis: natural and controlled direct effect analyses. *Pharmacoepidemiol Drug Saf.* 2023;32(4):407-15.

Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E, Solomon DH. Time-varying association of rheumatoid arthritis disease activity to subsequent cardiovascular risk. *ACR Open Rheumatol.* 2022;4(7):587-95.

Yun H, Chen L, Roy JA, Greenberg J, Harrold LR, George MD, Curtis JR. Rheumatoid arthritis disease activity and hospitalized infection in a large US registry. *Arthritis Care Res.* 2023;75(8):1639-47.

Curtis JR, Fiore S, Ford K, Janak JC, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk VP. Meaningful improvement and worsening in patients who do not achieve low disease activity and switch therapy to a new biologic or targeted disease-modifying antirheumatic drug: results from the CorEvitas RA Registry. *J Clin Rheumatol.* 2023;29(4):e47-e51.

Galvao RW, Curtis JR, Harrold LR, Wu Q, Xie F, George MD. Accuracy of administrative claims prescription fill data to estimate glucocorticoid use and dose in patients with rheumatoid arthritis. *Pharmacoepidemiol Drug Saf.* 2023;32(11):1271-9.

Harrold LR, Zueger P, Nowell WB, Blachley T, Schrader A, Lakin PR, Curtis D, Stradford L, Venkatachalam S, Tundia N, Patel PA. A real-world effectiveness study using a mobile application to evaluate early outcomes with upadacitinib in rheumatoid arthritis. *Rheumatol Ther.* 2023;10(6):1519-33.

Pappas DA, O'Brien J, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier DH. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry. *Arthritis Res Ther.* 2023;25(1):166.

Harrold LR, Wittstock K, Kelly S, Han X, Shan Y, Guo L, Moore PC, Khaychuk V. Comparative effectiveness of abatacept vs. tofacitinib in the subset of patients who are CCP+. *Rheumatol Ther.* 2023;10(3):575-587.

Sebba A, Bingham CO, Bykerk VP, Fiore S, Ford K, Janak JC, Pappas DA, Blachley T, Dave SS, Kremer JM, Yu M, Choy E. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: analysis from the CorEvitas RA Registry. *Clin Rheumatol* 2023;42(8):2037-51.

Solomon DH, Guan H, Johansson FD, Santacroce L, Malley W, Guo L, Litman H. Assessing clusters of comorbidities in rheumatoid arthritis: a machine learning approach. *Arthritis Res Ther.* 2023;25:224.

Matsson A, Solomon DH, Crabtree MM, Harrison RW, Litman HJ, Johansson FD. Patterns in the sequential treatment of patients with rheumatoid arthritis starting a biologic or targeted synthetic disease-modifying antirheumatic drug: 10-year experience from a US-based registry. *ACR Open Rheumatol.* 2024;6(1):5-13.

Dua AB, Ford K, Fiore S, Pappas DA, Janak JC, Blachley T, Roberts-Toler C, Emeanuru K, Kremer JK, Kivitz A. Clinical outcomes in patients with rheumatoid arthritis after switching between interleukin-6-receptor inhibitors and janus kinase inhibitors: findings from an observational study. *Rheumatol Ther.* 2023;10(6):1753-68.

Aripova N, Kremer JM, Reed GA, Pappas DA, Mikuls T. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. *Rheumatology.* 2024;63(2):542-550/

Besette L, Movahedi M, Reed G, Kremer JM, Kane K, Keystone E. Does the type of failure and the choice of the second biologic influence response and persistence on medication in rheumatoid arthritis? *J Clin Rheumatol.* 2023;29(7):332-340.

Capelli LC, Reed G, Pappas GA, Kremer JM. A model to predict future biological or targeted synthetic DMARD switch at a subsequent clinic visit in rheumatoid arthritis. *Rheumatol Ther.* 2023;10(6):1669-81.

Pala O, Reed G, Pappas DA, Harrold LR, Kremer JM. The impact of disease activity on patient-reported subjective cognitive decline (SCD) in patients with rheumatoid arthritis. *Exploration of Musculoskeletal Disease.* 2023;1:228-40.

Pappas DA, O'Brien J, Moore PC, Dodge R, Germino R, Masri KR, Bingham CO, Cappelli LC. Treatment patterns and effectiveness of tofacitinib in patients initiating therapy for rheumatoid arthritis: results from the CorEvitas Rheumatoid Arthritis Registry. *J Rheumatol.* 2024;51(5):452-61.

Baker JF, Zueger P, Ali M, Bennett D, Yu M, Munoz Maldonado Y, McLean RR. Real-world use and effectiveness outcomes in rheumatoid arthritis patients treated with upadacitinib: an analysis from the CorEvitas Registry. *Rheumatol Ther.* 2024;11(2):363-380.

Harrold LR, Wittstock K, Kelly S, Han X, Zhuo J, Schrader A, Middaugh N, Moore PC, Kaychuk V. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive. *Adv Rheumatol.* 2024;64(1):10.

O'Brien J, Park SH, Blachley T, Marchese M, Middaugh N, Wittstock K, Harrold LR. Disparities in burden of disease in patients with RA across racial and ethnic groups. *Clin Rheumatol.* 2024;43(3):921-7.

Curtis JR, McLean RR, Lee IH, Mackey RH, Moore PC, Haubrich R, Greenberg JD, Wu A. Prevalence and factors associated with patient-clinician discordance among patients with rheumatoid arthritis initiating advanced therapy. *ACR Open Rheumatol.* 2024;6(5):253-64.

Baker JF, Bakewell C, Dikranian A, Lam G, O'Brien J, Moore PC, Yu M, Hur P, Masri KR. Characteristics and 6-month outcomes in patients with rheumatoid arthritis initiating infliximab biosimilar IFX-dyyb in a real-world setting. *Rheumatol Ther.* 2024;11(3):841-53.

Harrold LR, O'Brien J, Moore P, Sima A, Yu M, Roberts-Toler C, Bingham C, Pope J, Masri K, Gegear K. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. *Clin Rheumatol.* 2025;44(2):635-48.

Fukui S, Winkelmayr WC, Tedeschi SK, Marrugo J, Guan H, Harrold LR, Litman HJ, Shinozaki T, Solomon DH. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. *Ann Rheum Dis.* 2025;84(2):201-9.

Pappas DA, Reed G, Kane K, Curtis JR, Charles-Schoeman C, Giles JT, Kremer JM. Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients. *Seminars in Arthritis and Rheumatism.* 2024;68:152504.

Litman HJ, Sheffield KM, Pugach O, Shan M, Lakin P, Cui ZL, Curtis SE, Johnston JA, Harrold LR. Applying bias correction methods to build hybrid controls using real-world patients for a phase IIb randomized controlled trial of baricitinib for rheumatoid arthritis. *Pharm Stat.* 2025;24(4):e70020.

Paudel ML, Shadick N, Weinblatt M, Reed G, Litman HJ, Kremer JM, Pappas DA, Solomon DH. Development and external validation of a multivariable predictive model for progression to difficult-to-treat rheumatoid arthritis in biologic-experienced patients. *Arthritis Res Care (Hoboken).* 2026;78(1):54-65.

RA Japan

Yamanaka H, Kishimoto M, Nishijima N, Yamashita K, Matsushima J, O'Brien J, Blachley T, Eliot M, Margolin Z, Dave SS, Tanaka Y. Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. *Mod Rheumatol*. 2023;34(1):27-36.

Tanaka Y, Kishimoto M, Sonomoto K, Amano K, Harigai M, Onofrei A, O'Brien J, Margolin Z, Barr C, Mizuno Y, Agarwal E, Sugiyama N, Yamanaka H. Methotrexate, tofacitinib, and biologic disease-modifying antirheumatic drug safety and effectiveness among patients with rheumatoid arthritis in Japan: CorEvitas Registry observational study. *Rheumatol Ther*. 2024;11(5):1237-53.

Abstracts & Presentations

Alopecia Areata

Senna MM, Craiglow B, Malley W, Wahl PM, McLean RR, King B. Characterization of treatment, disease burden, and patient-reported outcome measures in a real-world cohort of patients with alopecia areata: the CorEvitas Alopecia Areata Registry. AAD, Orlando, FL, March 7-11, 2025.

Atopic Dermatitis

Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Characterization of Disease Burden and Comorbidities in a Large, Real-World Cohort of Patients with Atopic Dermatitis: The Corevitas Atopic Dermatitis Registry. Fall Clinical, Las Vegas, NV, October 20-23, 2022. Encore Poster

Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Characterization of disease burden and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. EADV Congress 2022, Milan, Italy, September 7-11, 2022. Encore EPoster

Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Characterization of disease burden and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. Maui Derm NP&PA Summer, Colorado Springs, CO, June 23-25, 2022. Encore Poster

Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Characterization of disease burden and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. RAD 2022, Baltimore, MD, April 9-11, 2022. Encore Poster

Silverberg JI, Piece E, Feely M, Atwater AR, Schrader A, Jones E, Dave SS, Simpson E. Disease Burden Among Patients with Atopic Dermatitis Treated with Systemic Therapy for 4 to 12 Months. EADV Congress 2022, Milan, Italy, September 7-11, 2022. Eposter

Lio P, Simpson E, Pierce E, Cronin A, McLean R, Dave SS, Kovacik A, Feely M, Silverberg J. Impact of Atopic Dermatitis Lesion Locations on Patient Burden: A Real-world Study. AAD 2022, Boston, MA, March 25-29, 2022. Eposter

Silverberg J, Shi VY, Alexis A, Pierce E, Cronin A, McLean RR, Roberts-Toler C, Rueda MJ, Atwater AR, Simpson EL. Racial and ethnic differences in sociodemographic and treatment characteristics among patients with atopic dermatitis in the United States: Real-world data from CorEvitas registry. RAD 2022, Baltimore, MD, April 9- 11, 2022. Poster

Silverberg JI, Shi VY, Alexis A, Pierce E, Cronin A, McLean RR, Roberts-Toler C, Rueda MJ, Atwater AR, Simpson EL. Racial and Ethnic Differences in Sociodemographic and Treatment Characteristics Among Patients With Atopic Dermatitis in the United States: Real-world Data From CorEvitas Registry. DERM2022 NP/PA, Colorado Springs, CO, July 28-31, 2022. Encore Poster

Simpson EL, Jones EA, Cronin A, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Silverberg JI. Use of Systemic Therapy in Adults with Moderate-to-Severe Atopic Dermatitis: Analysis from the CorEvitas Atopic Dermatitis Registry. Fall Clinical, Las Vegas, NV, October 20-23, 2022. Encore Poster

Simpson EL, Jones EA, Cronin A, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Silverberg JI. Use of Systemic Therapy in Adults with Moderate-to-Severe Atopic Dermatitis: Analysis from the CorEvitas Atopic Dermatitis Registry. EADV Congress 2022, Milan, Italy, September 7-11, 2022. Encore EPoster

Simpson EL, Jones EA, Cronin A, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Silverberg JI. Use of Systemic Therapy in Adults with Moderate-to-Severe Atopic Dermatitis: Analysis from the CorEvitas Atopic Dermatitis Registry. Maui Derm NP&PA Summer, Colorado Springs, CO, June 23-25, 2022. Encore Poster

Simpson EL, Jones EA, Cronin A, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Silverberg JI. Use of Systemic Therapy in Adults with Moderate-to-Severe Atopic Dermatitis: Analysis from the CorEvitas Atopic Dermatitis Registry. RAD 2022, Baltimore, MD, April 9-11, 2022. Encore Poster

Silverberg J, Shi VY, Alexis A, Pierce E, Cronin A, McLean RR, Roberts-Toler C, Rueda MJ, Atwater AR, Simpson EL. Racial and Ethnic Differences in Sociodemographic and Treatment Characteristics Among Patients With Atopic Dermatitis in the United States: Real-world Data From CorEvitas Registry. Hawaii Derm Seminar, February 2023.

Silverberg JI, Gooderham M, Calimlim B, Grada A, Munoz Maldonado Y, Li A, Crabtree MM, Simpson E. Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): Results from cross-sectional analyses of the CorEvitas AD Registry. Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 10, 2023.

Simpson E, Fenske C, Dawson Z, Munoz Maldonado Y, Ho K, Li A, Callahan K. Evaluation of disease burden, patient characteristics, and associated treatment utilization among adults with atopic dermatitis, the CorEvitas Atopic Dermatitis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 19-22, 2023

Silverberg J, Augustin M, Eichenfield L, Lio P, Guttman-Yassky E, Reck Atwater A, Pierce E, Rueda MJ, Li A, Munoz Maldonado Y, Simpson E. A checklist to aid in identifying patients who are candidates for systemic therapy. Winter Clinical Dermatology Conference, Honolulu, HI, January 12-17, 2024.

Li A, Dawson Z, Munoz Maldonado Y, Ho K, Callahan K, Stein Gold L, Desai S, Golant A, DiRuggiero D, Silverberg JI. Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry. Spring RAD, Chicago, IL, June 8-10, 2024

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. Spring RAD, Chicago, IL, June 8-10, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. Spring RAD, Chicago, IL, June 8-10, 2024.

Simpson E, Fenske C, Dawson Z, Munoz Maldonado Y, Ho K, Li A, Callahan K. Evaluation of disease burden, patient characteristics, and associated treatment utilization among adults with atopic dermatitis, the CorEvitas Atopic Dermatitis Registry. AAD, San Diego, CA, March 8-12, 2024.

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. GDPA Dermatology PEARLS Conference, Atlanta, GA, September 5-7, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. GDPA Dermatology PEARLS Conference, Atlanta, GA, September 5-7, 2024.

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. Maui Derm NP+PA Fall, Nashville, TN, September 15-18, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. Maui Derm NP+PA Fall, Nashville, TN, September 15-18, 2024.

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. Las Vegas Dermatology Seminar, Las Vegas, NV, September 19-21, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. Las Vegas Dermatology Seminar, Las Vegas, NV, September 19-21, 2024.

Silverberg JI, Gooderham M, Bunick CG, Calimlim B, Grada A, Munoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): results from longitudinal analyses of the CorEvitas AD Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 24-27, 2024.

Silverberg JI, Gooderham M, Bunick CG, Calimlim B, Grada A, Munoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD) in bio-experienced and bio-naive patients: results from longitudinal analyses of the CorEvitas AD Registry. RAD, Nashville, TN, June 6-7, 2025.

Gandhi S, Gershenson B, Chubb H, Cherry B, Rubin N, Barr CJ, Moore-Clingenpeel M, Pappas DA, Fan H, Lumpan C, Weissert J, Biswas P, Chan G. Real-world prospective data assessing the long-term safety of abrocitinib treatment in adults with moderate to severe atopic dermatitis (AD): over two years of experience from the CorEvitas AD Registry. ICPE, Washington, DC, August 22-26, 2025.

Simpson E, Prajapati VH, McCann WA, Dawson Z, Pierce E, Li AH, Choi CJ, Silverberg J. Lebrikizumab patients treated in the real world: first North American data from the PPD CorEvitas AD Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 23-26, 2025.

Silverberg JI, Gooderham M, Bunick CG, Calimlim B, Grada A, Munoz Maldonado Y, Li AH, Fergestrom N, Simpson E. Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis: results from longitudinal analyses in 6- and 12-month cohorts for the PPD CorEvitas Atopic Dermatitis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 23-26, 2025.

CERTAIN

Cohen S, Mellors T, Zhang L, Jones A, Connolly-Strong E, Pappas DA, Kremer JM, Withers JB, Akmaev VR. A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months. ACR, Virtual, November 5-9, 2021. Poster

Curtis JR, Kremer JM, Pappas DA, Zhang L, Connolly-Strong E, Withers JB, Akmaev VR, Saleh A. Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor- α Inhibitor Therapies. ACR, Virtual, November 5-9, 2021. Poster

Coras R, Alotaibi M, Pappas DA, Kremer JM, Kavanaugh A, Mikuls T, Thiele G, Jain M, Guma M. Bioactive Lipid Profiling Can Identify Dynamic Biomarkers in Response to Biologic Therapy Result of the CorEvitas CERTAIN Comparative Effectiveness Study. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster

Alotaibi M, Coras R, Pappas DA, Mikuls T, Thiele G, Kremer JM, Jain M, Guma M. Different Bioactive Lipid Profiles Predict Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study. EULAR 2022, Copenhagen, Denmark, June 1-4, 2022. Poster

Inflammatory Bowel Disease

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK. Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From CorEvitas' Inflammatory Bowel Disease Registry. ACG, Las Vegas, NV, October 22-27, 2021. EPoster and Poster

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK; Change in Urgency Status Among Ulcerative Colitis Patients: Understanding the Impact of Treatment Changes from the CorEvitas Inflammatory Bowel Disease Registry. ECCO, Copenhagen, Denmark, July 7-10, 2021, EPoster

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK. Change in Urgency Status Among Ulcerative Colitis Patients: Understanding the Impact of Treatment Changes From The CorEvitas Inflammatory Bowel Disease Registry. C&C Congress 2022, Virtual, January 20-22, 2022. Encore. Poster

Feagins LA, Moore P, Crabtree MM, Loughlin AM, Gaidos JK. Impact of Fatigue on Work Productivity and Activity Impairment and Health Care Utilization in Patients with Inflammatory Bowel Disease. ACG 2022, Charlotte, NC, October 21-26, 2022. Poster Presentation In-Person and On-Line

Cross RK, Griffith J, Kujawski MR, Beeghly A, Middaugh N, Moore P, Choi CJ, Gurrola M, Sharma D. Corticosteroid use among patients with Crohn's disease and ulcerative colitis on advanced therapy from the CorEvitas Inflammatory Bowel Disease Registry. ACG 2023, Vancouver, BC, Canada, October 20-25, 2023.

Horst S, Marchese M, Gurrola M, Hudesman D, Singh Kocchar G, Wolf D, Sauk J, Abraham B, Beeghly A. Anxiety, depression, and advanced therapy drug survival among patients with inflammatory bowel disease (IBD) in the CorEvitas IBD Registry. DDW 2025, San Diego, CA, May 3-6, 2025.

Cross RK, Griffith J, Beeghly A, Crabtree M, Gurrola M, Kim JR, Korzenik J. Real-world effectiveness of risankizumab on clinical and patient-reported outcomes in patients with moderate-to-severe Crohn's disease in the PPD CorEvitas Inflammatory Bowel Disease Registry. ACG, Phoenix, AZ, October 24-29, 2025.

Multiple Sclerosis

Kantor D, Bebo B, Wahl PM, Coyle PK, Fox EJ, Bermel RA, Riolo J, Silva D, Wright C, Malley W, Janak J, Miller A. Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry. CMSC 2021, Orlando, FL and Virtual, October 25-28, 2021. EPoster

Kantor D, O'Brien J, Malley M, Biswas M, Silva D, DeBoer E, Margolin Z, Roberts-Toler C, Zivadinov R, Dwyer M, Bergsland N, Wahl PM, Miller A. Linking imaging and clinical data in a real-world setting: first findings from the qMRI sub-study in CorEvitas MS Registry.ECTRIMS-ACTRIMS Meeting, Milan, Italy, October 11-13, 2023.

Multiple registries

Hudesman D, Mease P, Lebwohl M, Loughlin AM, Moore P, Janak J, Lemay CA, Korzenik J, Cross RK. The burden of work productivity and activity impairment in Crohn's disease, ulcerative colitis, psoriasis and psoriatic arthritis. DDW, Virtual, May 21-23, 2021. Session Title: IBD: Natural History and Outcomes (5/22/21). Poster of Distinction

Sima AP, Maldonado YM, Pugach O. Addressing the impact of group imbalance on standardized effect size measures in real-world evidence studies. ENAR Spring Conference, Nashville, TN, March 19-22, 2023.

NMOSD

Exuzides A, Gholizadeh S, Sidiropoulos P, Middaugh N, Crabtree M, Cronin A, Pappas DA, Behne J, Bennett JL, Blaschke TF, Cook LJ, Levy M, Lewis KE, Smith TJ, Weinshenker B, Wingerchuk D, Yeaman MR. Baseline Characteristics of Initial Patients in the CorEvitas SPHERES Registry for NMOSD.ECTRIMS 2022, Amsterdam, October 26-28, 2022. Poster

Harrold LR, Cohen L, Cronin A, Bennett JL, Levy M, Weinshenker B, Wingerchuk D, Lewis K, Cook LJ, Blaschke TF, Smith TJ, Yeaman MR, Pappas DA. SPHERES: Innovative Registry Addressing the New Era of NMOSD Therapy. ACTRIMS Forum, West Palm Beach, FL, February 24-26, 2022. Poster

Levy M, Cavida D, Patterson KR, Wani RJ, Meyers A, Middaugh N, Choi CJ, Gurrola M, Bennett JL. Inebilizumab for treatment of NMOSD in a real-world cohort: analysis from the SPHERES Registry.ECTRIMS, Barcelona, Spain, September 24-26, 2025.

Levy M, Cavida D, Patterson KR, Wani RJ, Meyers A, Gurrola M, Choi CJ, Middaugh N, Bennett JL. NMOSD treatment patterns in the era of approved biologics: an analysis from the SPHERES Registry.ECTRIMS, Barcelona, Spain, September 24-26, 2025.

PsA/SpA

Mease PJ, Marchese M, McClean R, Blachley T, Anatale-Tardiff L, Saffore C, Lesser E, Ogdie A. Comparison of Baseline Disease Activity and Patient (Pt)-Reported Outcomes (PROs) Between Pts With Psoriatic Arthritis and Axial Involvement (Axial PsA) and Axial Spondyloarthritis (Axial SpA) From the Corrona PsA/SpA Registry. OP0049, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.137

Mease PJ, Merola JF, Chakravarty SD, Lin I, Malley W, McLean RR, Spitzer RL, Kavanaugh A, Ogdie-Beatty A. Characteristics of Real-world Psoriatic Arthritis Patients Initiating Guselkumab: Findings from CorEvitas' PsA/SpA Registry. Maui Derm, Maui, HI, January 24-28, 2022. Abstract & Poster

Mease PJ, Ogdie A, Chakravarty SD, Shiff NJ, Lin I, Malley W, McLean RR, Spitzer RL, Kavanaugh A, Merola JF. Characteristics of Real-World Psoriatic Arthritis Patients Initiating Guselkumab: Findings from the CorEvitas PsA/SpA Registry. RWCS, Maui, HI, February 16-19, 2022. Encore. Abstract

Mease PJ, Ogdie A, Chakravarty SD, Shiff NJ, Lin I, Malley W, McLean RR, Spitzer RL, Kavanaugh A, Merola JF. Characteristics of Real-World Psoriatic Arthritis Patients Initiating Guselkumab: Findings From the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. CCR East 2022, Destin, FL. May 12- 15, 2022. Encore Poster

Ogdie A, O'Brien J, Malley W, Kohl E, Orroth K, Klyachkin Y, Cordey M, and Mease P. Effectiveness by Disease Severity in Patients with Psoriatic Arthritis (PsA) Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Middaugh N, Malley W, Spitzer RL, Broadwell A, Kavanaugh A, Merola JF. Effectiveness of Guselkumab Among Real-world Psoriatic Arthritis Patients in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. CCR West 2022, October 20-23, 2022, Poster

Mease PJ, Nowak M, Choi J, Lehman T, Sreih A, Blachley T, Dube B, Ho K, Middaugh N, Ogdie A. Impact of Delay of Treatment With Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from The CorEvitas PsA/SpA Registry. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster

Mease P, Ogdie A, Pappas DP, Reed G, Kremer. Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster

Mease PJ, Blachley T, O'Brien J, Middaugh N, Kricorian G, Stryker S, Collier D, Ogdie A. Real-world Evidence on Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR 2022, Copenhagen, Denmark, June 1-4, 2022. Poster Display and Tour

Mease P, McLean RR, Blachley T, Middaugh N, Mittal M, Clewell J, Jones H, Ogdie A. The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control in Patients with Axial Spondyloarthritis: A Study from the CorEvitas PsA/SpA Registry. ACR 2022, Philadelphia, PA, November 11-16, 2022. Ignite Talk and Virtual Poster

Ogdie A, McLean RR, Blachley T, Middaugh N, Mittal M, Clewell J, Ciecinski S, Mease P. The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR 2022, Philadelphia, PA, November 11-16, 2022. Oral Presentation

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults With Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. RhAPP, Phoenix, September 21-23, 2023. Encore poster.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults With Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. CCR West, San Diego, September 7-10, 2023. Encore poster.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults With Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. RNS Conference, Austin, TX, August 2-5, 2023. Encore poster.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults With Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Maui Derm NP + PA, Colorado Springs, CO, June 21-24, 2023.

Ogdie A, McLean RR, Blachley T, Middaugh N, Mittal M, Clewell J, Ciecinski S, Mease P. The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Sociedad Española de Reumatología (SER), Seville, Spain, May 9-12, 2023.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. RWCS, Maui, HI, February 15 - 18, 2023.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. State of Texas Association of Rheumatologists (STAR) Conference, Houston, TX, February 3-5, 2023.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Maui Dermatology Conference, Maui, HI, January 23-27, 2023.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. CCR West 2023, San Diego, CA, September 7-10, 2023.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Maui Derm NP+PA Fall 2023, Asheville, NC, September 27-30, 2023.

Ogdie AR, Song C, Middaugh N, Marchese M, Eliot M, Beaty S, Low R, Mease PJ. Durability of response among psoriatic arthritis (PsA) patients using b/tsDMARDs in the CorEvitas PsA/Spondyloarthritis (SpA) Registry. ACR Convergence, San Diego, CA, November 10-15, 2023.

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Improvements in patient-reported outcomes through 6 months of guselkumab treatment in patients with active psoriatic arthritis: Real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. ACR Convergence, San Diego, CA, November 10-15, 2023.

Ogdie A, Middaugh N, Choi J, Zema C, Kelleman M, Dahan S, Dodge R, Nowak M, Varga S, Mease PJ. Drug survival of first-line TNFi and apremilast and description of second-line therapy among psoriatic arthritis (PsA) patients in the CorEvitas PsA/Spondyloarthritis (SpA) Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024

Mease PJ, Saffore CD, Ye X, Nakasato P, Kelleman M, Middaugh N, Ho K, Ogdie A. Real-world disease burden by articular involvement among patients with psoriatic arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Mease PJ, Ye X, Saffore CD, Parikh B, Ciecinski S, Blachley T, Eliot M, Middaugh N, Ogdie A. Real-world burden of uncontrolled disease despite treatment with tumor necrosis factor inhibitors among psoriatic arthritis patients in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Ogdie A, Ye X, Saffore CD, Parikh, Iyile T, Blachley T, Eliot M, Middaugh N, Mease PJ. Real-world burden of uncontrolled disease despite treatment with tumor necrosis factor inhibitors among axial spondyloarthritis patients in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Shiff NJ, Mease PJ, Ogdie A, Tesser J, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Improvements in patient-reported outcomes through 6 months of guselkumab treatment in patients with active psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Ogdie A, Middaugh N, Marchese M, Walsh J, Bello N, Lisse J, Kronbergs A, Grace E, Ngantcha M, Mease P. Cycling to TNFi vs. switching to IL-17Ai after a first TNFi discontinuation among patients with PsA and AxSpA: the CorEvitas PsA/SpA Registry. ACR Convergence 2024, Washington, DC, November 14-19, 2024.

Mease P, Ye X, Saffore C, Iyile T, Nakasato P, Blachley T, Lakin PR, Middaugh N, Ogdie A. Benefits of achieving early versus late clinical response after treatment with biologic and targeted synthetic DMARDs among patients with PsA in the CorEvitas PsA/Spondylarthritis Registry. ACR Convergence 2024, Washington, DC, November 14-19, 2024.

Ogdie A, Middaugh N, Blachley T, Bourgeois T, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ. Effectiveness of tofacitinib monotherapy versus combination therapy in patients with psoriatic arthritis: results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry. ACR Convergence 2024, Washington, DC, November 14-19, 2024.

Mease PJ, Middaugh N, Munoz Maldonado Y, Song C, Eliot M, Low R, Ogdie A. Persistence and disease activity control among patients with psoriatic arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry initiating a third or higher line of biologic or targeted disease-modifying antirheumatic drug therapy. ACR Convergence, Chicago, IL, October 24-29, 2025.

Psoriasis

Strober B, Cronin, C, Lin TC, O'Brien J, Emeauru K, Kang HJ, Nunez-Gomez N, Khilfeh I, Lebwohl M. Characteristics and Disease Burden in Patients With Mild to Moderate vs. Severe Plaque Psoriasis in Real-World Settings: Results From the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Lebwohl M, Kotowsky N, Medeiros RA, Nicole N, Janak J, Valdecantos WC, Flack M, Amanda K Golembesky AK, Strober B. Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American-based Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Strober B, Kotowsky N, Medeiros RA, Nicole N, Janak J, Valdecantos WC, Flack M, Amanda K Golembesky AK, Lebwohl M. Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis versus plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Armstrong AW, Duffin KC, Fitzgerald T, Teeple A, Uy JP, Olurinde M, Rowland K, McLean RR, Guo L, Shan Y, Van Voorhees AS. Effectiveness of guselkumab among patients with severe plaque psoriasis in the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Armstrong AW, Duffin KC, Fitzgerald T, Teeple A, Uy JP, Olurinde M, Rowland K, McLean RR, Guo L, Shan Y, Van Voorhees AS. Impact of guselkumab on quality of life and work productivity outcomes among patients with severe plaque psoriasis in the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Enos CW, Ramos V, Lin T, McLean RR, Foster N, Dube B, Van Voorhees AS. Characteristics of Patients with Psoriasis Differ by Obesity Status and History of Metabolic Comorbidities. AAD VMX, Virtual, April 23-25, 2021, Poster

Enos CW, Ramos V, Lin T, McLean RR, Foster N, Dube B, Van Voorhees AS. Psoriatic Disease Characteristics by Metabolic Comorbidities among Patients with Psoriasis. AAD VMX, Virtual, April 23-25, 2021, Poster/Presentation

Ogdie-Beatty A, Strober B, Lebwohl M, Cronin A, Lin TC, Kang HJ, Middaugh N, O'Brien J, Jardon S, Richter S, Klyachkin Y, Mease PJ. Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas' Psoriasis Registry. ACR, Virtual, November 5-9, 2021. Poster

Strober B, Callis Duffin K, Lebwohl M, Lin TC, Janak JC, Patel M, Photowala H, Vishvas Garg V, Bagel J. Indirect Costs Due to Work Productivity Loss in Patients With Psoriasis in the United States: Analysis of the CorEvitas Psoriasis Registry. AMCP Nexus 2021, Denver, CO, October 19-21, 2021. Poster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Russel Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. AOCD New Trends in Dermatology Virtual Meeting & Expo, October 7-10, 2021. Encore Poster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R, Stenger KB (presenter). Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. CCR-East 2021, Destin, FL, August 12-15, 2021. EPoster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R, Wenda R, Zick (Non-author presenter). Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. CCR-West 2021, San Diego, CA, September 18- 21, 2021. EPoster

Gang W, Burge R, Erjia Y, Guanshen D, Harrison RW, McLean RR, Kerti J, Bagel J. Effectiveness of biologic therapy for psoriasis in Asian and Caucasian patients: A retrospective analysis from CorEvitas' Psoriasis Registry. Chinese Dermatologist Association 17th Annual Meeting in China, Abstract

Strober B, Kotowsky N, Medeiros RA, Foster N, Janak J, Valdecantos WC, Flack M, Duan S, Golembesky AK, Lebwohl M. Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis versus plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. CSD, China, June 17-20, 2021. Poster

Strober B, Cronin A, Lin TC, O'Brien J, Kang HJ, Jardon S, Richter S, Khilfeh I, Lebwohl M. Analysis of Real-world Systemic-Naive Patients With Mild or Moderate vs Severe Plaque Psoriasis: Patient Characteristics and Disease Burden Findings From the Corrona Psoriasis Registry. EADV 2021, Vienna, Austria, September 29- October 2, 2021. EPoster

Strober B, Ferris LK, Callis Duffin K, Janak JC, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong AW. Real-World Effectiveness of Risankizumab in Patients With Moderate to Severe Psoriasis Using the CorEvitas Psoriasis Registry. FCD 2021, Las Vegas, NV, October 21-24, 2021. EPoster

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. The Evolving Treatment Approach of Secukinumab in Biologic-Experienced and Biologic-Naive Patients With Psoriasis: Key Clinical and Patient Characteristics by Year of Treatment Initiation in a US-Based Registry. FCD 2021, Las Vegas, NV, October 21-24, 2021. EPoster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. FSR 2021, Lake Buena Vista, FL, July 9-11, 2021. EPoster

Gulliver W, See K, Zhu B, Malatestinic W, Konicek B, Harrison RW, McLean RR, Kerti S, Anatale-Tardiff L, Burge R, Leonardi C. Development and Validation of Optimal Psoriasis Assessment Tools (OPAT) Among Patients in the Corrona Psoriasis Registry. IFPA, Stockholm, Sweden, July 1-3, 2021, EPoster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the Corrona Psoriasis Registry. Innovations in Dermatology, Fall Virtual, September 17-20, 2021. EPoster

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Secukinumab Provides Sustained Improvement on Clinical and Patient-Reported Outcomes Through 12 Months in Both Biologic-Naive and Biologic-Experienced Patients With Psoriasis in a US Real-World Setting. Innovations in Dermatology, Fall Virtual, September 17-20, 2021. EPoster

Strober B, Callis Duffin K, Lebwohl M, Lin TC, Janak J, Longcore M, Patel M, Photowala H, Garg V, Bagel J. Association of Psoriasis Disease Severity With Patient-Reported Outcomes Among US and Canadian Patients: Analysis of the Corrona Psoriasis Registry. Innovations in Dermatology (Hawaii and Caribbean Derm), Virtual, March 16-20, 2021, EPoster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the Corrona Psoriasis Registry. Innovations in Dermatology (Hawaii and Caribbean Derm), Virtual, March 16-20, 2021, EPoster

Strober B, Lebwohl M, Kotowsky N, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK. Perspectives on generalized pustular psoriasis treatment in North America: survey results from dermatologists in the Corrona Psoriasis Registry. Maui Derm, Maui, HI, January 25-29, 2021, EPoster

Strober B, Patil D, McLean R, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Impact of Secukinumab on Clinical and Patient-Reported Outcomes in Biologic- Naive Patients With Psoriasis in a US Real-World Setting. Maui Derm NP+PA 2021 Fall, Asheville, NC, September 29 – October 2, 2021. Poster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. Maui Derm NP+PA Summer, Colorado Springs, CO, June 23-26, 2021. EPoster

Enos CW, Yi JZ, McLean RR, Sima AP, Kohl EA, Eckmann T, Van Voorhees AS. Assessment of racial and ethnic differences in treatment response to biologic therapy among psoriasis patients enrolled in CorEvitas' Psoriasis Registry. NPF Research 2021, New York, NY, September 10, 2021. Poster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. RNS Virtual 2021, August 4-7-2021, EPoster

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. SDDS June 2021, San Diego, CA, June 11-13, 2021, EPoster

Strober B, Patil D, McLean R, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Impact of Secukinumab on Clinical and Patient-Reported Outcomes in Biologic- Naive Patients With Psoriasis in a US Real-World Setting. SDPA Summer 2021, Chicago, IL , July 22-25, 2021. EPoster

Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE, Zhuo J, Patel V, Mease PJ. Psoriatic Arthritis Risk in Psoriasis Patients in the Corrona® Psoriasis Registry. SID, Virtual, May 3-8, 2021, EPoster.

Enos C, Ramos VL, Lin TC, McLean RR, Foster N, Dube B, Van Voorhees AS. Proportions of biologic discontinuation among psoriasis patients with metabolic comorbidities. SID, Virtual, May 3-8, 2021, EPoster.

Strober B, Lebwohl M, Kotowsky N, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK. Flare characteristics of generalized pustular psoriasis in North America: survey results from dermatologists in the Corrona Psoriasis Registry. Winter Clinical Derm, Maui, HI, January 15-20, 2021, EPoster

Lebwohl M, Fitzgerald T, Teneralli RE, Janak J, Marchese M, Rowland K, Choi O, Chan D, Lesser E, Cameron M, Strober BE. 24 Month Drug Persistence of Guselkumab as Compared to Other Biologic Therapies in Biologic-Experienced Plaque Psoriasis Patients. Fall Clinical, Las Vegas, NV, October 20-23, 2022. Poster

Strober BE, Fitzgerald T, Teneralli RE, Janak J, Marchese M, Rowland K, Choi O, Chan D, Lesser E, Cameron M, Lebwohl M. 24 Month Drug Persistence of Guselkumab in Biologic-Naïve Plaque Psoriasis Patients. Fall Clinical, Las Vegas, NV, October 20- 23, 2022. Poster

Strober B, Cronin A, Lin TC, O'Brien J, Kang HJ, Jardon S, Richter S, Khilfeh I, Lebwohl M. Analysis of Real-world Systemic-Naive Patients With Mild or Moderate vs Severe Plaque Psoriasis: Patient Characteristics and Disease Burden Findings From CorEvitas' Psoriasis Registry. WCD, Kauai, HI, January 14-19, 2022. Encore. Poster

Ogdie-Beatty A, Strober B, Lebwohl M, Cronin A, Lin TC, Kang HJ, Middaugh N, O'Brien J, Jardon S, Richter S, Klyachkin Y, Mease PJ. Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas' Psoriasis Registry. CCR East 2022, Destin, FL. May 12-15, 2022. Encore Poster

Ogdie A, Strober B, Lebwohl M, Cronin A, Lin T, Kang HJ, Middaugh N, O'Brien J, Jardon S, Klyachkin Y, Mease PJ. Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid Psoriatic Arthritis: Analysis of the CorEvitas Psoriasis Registry. CCR West 2022, October 20-23, 2022. Encore Poster

Blauvelt A, McLean RR, Beaty S, Sima AP, Low R, Jones EA, Stark JL, Lesser E, McClung L, Spitzer RL, Bagel J. Disease Burden of Patients with Psoriasis who Switch Biologic Therapy in Real-World Settings. Fall Clinical, Las Vegas, NV, October 20-23, 2022. Poster

McLean RR, Sima AP, Beaty S, Low R, Spitzer RL, Stark J, McLung L, Armstrong A. Durability of Response Among Psoriasis Patients Using Biologics: The CorEvitas Psoriasis Registry. Maui Derm, Maui, HI, January 24-28, 2022. Abstract & Poster

Russo G, Sima AP, Janak JC, Kohl EA, Lesser E, Marushchak O, Lebwohl M. Factors Impacting Drug Survival for Currently FDA-approved Biologic Therapies for Psoriasis at One-Year of Treatment. AAD 2022, Boston, MA, March 25-29, 2022. Oral Presentation

Khattri S, Merola JF, Yang YW, Fitzgerald T, Janak J, Teneralli RE, Sima A, Lesser E. Fatigue and Health-Related Quality of Life and Impairment Outcomes in Psoriasis Patients with and without Self-Reported Psoriatic Arthritis. Maui Derm NP&PA Summer, Colorado Springs, CO, June 23-25, 2022. Poster

Strober BE, Armstrong AW, Fitzgerald T, Janak J, Rowland K, Choi O, Chan D, Marchese M, Teneralli RE, Kang HJ. Long-term effectiveness of guselkumab on disease severity in the CorEvitas Psoriasis Registry. ID – Spring 2022, Scottsdale, AZ, April 27-30, 2022. Poster

Strober BE, Armstrong AW, Fitzgerald T, Janak J, Rowland K, Choi O, Chan D, Marchese M, Teneralli RE, Kang HJ. Long-term effectiveness up to 24 months of guselkumab on patient-reported outcomes in the CorEvitas Psoriasis Registry. Maui Derm NP&PA Summer, Colorado Springs, CO, June 23-25, 2022. Poster

Khattri S, Merola JF, Yang YW, Fitzgerald T, Janak J, Teneralli RE, Sima A, Lesser E. Prevalence, severity, and impact of fatigue in psoriasis patients with and without self-reported psoriatic arthritis. ID – Spring 2022, Scottsdale, AZ, April 27-30, 2022. Poster

Enos CW, Yi JZ, McLean RR, Sima AP, Kohl EA, Eckmann T, Van Voorhees AS. Racial/ethnic differences in biologic treatment patterns among patients in the CorEvitas. SID, Portland, OR, May 18-21, 2022. Poster

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowala H, Garg V, Strober BE. Real-World Achievement of Absolute Psoriasis Area and Severity Index Thresholds With Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. EADV Congress 2022, Milan, Italy, September 7-11, 2022. EPoster

Strober BE, Ferris LK, Duffin KC, Janak JC, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong AW. Real-World Patient-Reported Outcomes with Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. AAD 2022, Boston, MA, March 25-29, 2022. EPoster and Oral Presentation

Armstrong AW, Ferris LK, Duffin KC, Janak JC, Sima A, Eckmann T, Photowala H, Patel M, Garg V, Strober BE. Real-World Treat-to-Target Skin Clearance with Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. AAD 2022, Boston, MA, March 25-29, 2022. EPoster

Ogdie A, Strober B, Lebwohl M, Cronin A, Kang HJ, Middaugh N, O'Brien J, Jardon S, Richter S, Mease PJ. Relationship Between Skin Involvement and Disease Burden in Patients With Mild to Moderate Plaque Psoriasis: Real-World Findings From CorEvitas' Psoriasis Registry. AAD 2022, Boston, MA, March 25-29, 2022. EPoster and Oral Presentation

Ogdie A, Strober B, Lebwohl M, Cronin A, Middaugh N, O'Brien J, Kang HJ, Jardon S, Richter S, Mease PJ. Relationship Between Skin Involvement and Disease Burden in Patients With Mild to Moderate Plaque Psoriasis: Real-World Findings From the CorEvitas Psoriasis Registry. The Corevitas Atopic Dermatitis Registry. Fall Clinical, Las Vegas, NV, October 20-23, 2022. Encore Poster

Strober B, McLean R, Zhong Y, Davidson D, Kisa R, Spitzer R, Sima A, Lakin P, Zhuo J. Unmet Needs in Skin and Joint Symptoms: Control and Impact on Quality of Life in Actively Treated Patients With Psoriasis. EADV Congress 2022, Milan, Italy, September 7-11, 2022. Encore EPoster

Strober BE, McLean RR, Zhong Y, Davidson D, Kisa RM, Spitzer RL, Sima AP, Lakin P, Zhuo J. Unmet Needs in Skin and Joint Symptoms: Control and Impact on Quality of Life in Actively Treated Patients with Psoriasis. EADV Spring 2022, Ljubljana, May 12-14, 2022. EPoster

Philip J. Mease, Eric Jones, Adam Sima, Silky Beaty, Robert Low, Braulio Gomez, Marie Gurrola, Mark Lebwohl. Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry. EULAR 2023, Milan, Italy, May 31-June 3, 2023.

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Photowala H, Patel M, Garg V, Strober BE. Real-World Treat-to-Target Skin Clearance with Risankizumab in Patients with Moderate to Severe Psoriasis from the CorEvitas Psoriasis Registry. Congreso Colombiano de Dermatologia, Pereira, Colombia, February 23-26, 2023. Encore poster

Enos C, Munoz Maldonado Y, Kang HJ, McLean RR, Van Voorhees A. Diabetes is associated with worse response to biologics at 12-months among patients with plaque psoriasis in the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023

Yeroushalmi S, Cronin A, Roberts-Toler C, Gondo G, Wallace E, Reddy S, Han G, Kaffenberer J, Bhutani T, McLean RR, Liao W. Identification of Demographic and Clinical Features Associated with Multi-Biologic Failure in the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023.

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowla H, Garg V, Strober BE. Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023. Encore poster.

Strober BE, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowla H, Garg V, Armstrong AW. Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023. Encore poster.

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. Winter Clinical Dermatology Conference, Miami, FL, February 17-20, 2023.

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. Winter Clinical Dermatology Conference, Kohala Coast, HI, January 13-17, 2023.

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowla H, Garg V, Strober BE. Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. Maui Derm, Maui, HI, January 23-27, 2023.

Lebwohl M, Armstrong AW, Sima A, Gooderham M, McLean R, Papp K, Merola J, Gottlieb AB, Kisa R, Napoli A, Zhuo J, Varga S, Strober B. The Registry of Psoriasis Health Outcomes: a longitudinal real-world collaboration study (RePhlect) - North American Registry design. EADV Congress, Berlin, Germany, October 11-14, 2023.

Armstrong AW, Ferris LK, Callis Duffin K, Sima A, Eckmann T, Beeghly A, Patel M, Photowala H, Garg V, Strober BE. Real-world achievement of absolute Psoriasis Area and Severity Index thresholds with persistent 18-month rizankizumab use in patients with moderate to severe psoriasis from a North American registry. EADV Congress, Berlin, Germany, October 11-14, 2023.

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. EADV Congress, Berlin, Germany, October 11-14, 2023.

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. National Psoriasis Foundation Dermatology Residents and Rheumatology Fellows Meeting on Psoriatic Disease, Washington, DC, October 7-8, 2023.

Lebwohl M, Strober B, Schrader A, Li AH, Eckmann T, Zhu B, Malatestinic WN, Birt J, Feely M, Blauvelt A. 6-month real world study to assess the effectiveness of ixekizumab after switching from other biologic therapies: the CorEvitas Psoriasis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 19-22, 2023.

Mease PJ, Jones E, Sima A, Beaty S, Low R, Gomez B, Gurrola M, Lebwohl M. Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 19-22,2023.

Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Real-world application of International Psoriasis Council guidelines for prescribing systemic treatment to patients with psoriasis in North America. AAD, San Diego, CA, March 8-12, 2024.

Strober B, Zhong Y, Varga S, Zhuo J, Napoli A, Sima A, Beeghly A, Lebwohl M. Treatment discontinuation patterns in patients with psoriasis receiving apremilast in North America: a registry-based analysis. AAD, San Diego, CA, March 8-12, 2024.

Lebwohl M, Armstrong AW, Sima A, Gooderham M, Papp KA, Merola JF, Gottlieb AB, Napoli A, Zhuo J, Varga S, Strober B. The Registry of Psoriasis Health Outcomes (RePhlect): Characteristics of early adopters of deucravacitinib in the North American region. AAD, San Diego, CA, March 8-12, 2024.

Saal RC, Borda LJ, Li A, Choi J, Eckmann T, Encarnacion INM, Ormazza Vera A, Enos CW, Van Voorhees AS. Patterns of systemic treatment in psoriasis patients with a history of malignancy. SID Annual Meeting, Dallas, TX, May 15-18, 2024.

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang H, Ceja S, Khattri S, Stein Gold L. Patient-reported outcomes among plaque psoriasis patients initiating biologics in the CorEvitas Psoriasis Registry are similar regardless of extent of body surface area involvement. Maui Derm NP + PA Summer 2024, Colorado Springs, CO, June 19-22, 2024.

Strober B, Patel M, Photowala H, Kaldas MI, Garg V, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-world achievement of skin clearance targets and improved quality of life with risankizumab in patients with moderate psoriasis: 1-year results from the CorEvitas Psoriasis Registry. Maui Derm Hawaii 2024, Maui, HI, January 22-26, 2024.

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Photowala H, Patel M, Garg V, Strober BE. Long-term real-world achievement of skin clearance treatment targets and maintenance of response with risankizumab in patients with moderate to severe psoriasis: 2-year results from the CorEvitas Psoriasis Registry. AAD, San Diego, CA, March 8-12, 2024.

Armstrong AW, Ferris LK, Callis Duffin K, Sima AP, Eckmann T, Beeghly A, Patel M, St John G, Garg V, Strober BE. Long-term real-world achievement of skin clearance treatment targets with persistent 24-month risankizumab use in patients with moderate-severe psoriasis, with and without prior biologic experience, from the CorEvitas Registry. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Lebwohl M, Armstrong AW, Sima A, Gooderham M, Papp KA, Merola JF, Gottlieb AB, Napoli A, Zhuo J, Varga S, Strober B. The Registry of Psoriasis Health Outcomes (RePhlect): Characteristics of early adopters of deucravacitinib in the North American region. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Armstrong AW, Lebwohl M, Merola J, Gottlieb AB, Papp KA, Gooderham M, Varga S, Zhuo J, Napoli A, Fergestrom N, Sima A, McLean RR, Strober B. Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: 6-month analysis of skin clearance from the RePhlect Registry. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Strober B, Armstrong AW, Merola JF, Gottlieb AB, Papp KA, Gooderham M, Varga S, Zhuo J, Napoli A, Fergestrom N, Sima A, McLean RR, Lebwohl M. Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: 6-month analysis of symptom and quality of life improvements from the RePhlect Registry. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Singleton M, Pugach O, Eliot M, McLean RR, Sima A, Litman HJ. Performance of entropy balancing and covariate balancing propensity score methods for controlling confounding under challenging real-world conditions in observational studies: simulation study in the CorEvitas Psoriasis Registry. ISPE Annual Meeting, Berlin, Germany, August 24-28, 2024.

Strober B, Patel M, Kaldas MI, St John G, Garg V, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-world achievement of skin clearance targets and improved quality of life with risankizumab in psoriasis patients with moderate skin involvement (BSA \geq 3-10%). Fall Clinical Dermatology Conference, Las Vegas, NV, October 24-27, 2024.

Lockshin B, Blachley T, Eliot M, Beeghly A, Barghout V, Mathew J, Ferro T. Real-world tildrakizumab persistence in the US by biologic experience and insurance coverage in the PPD CorEvitas Psoriasis Registry. SDPA Summer, Washington, DC, June 25-29, 2025.

Litman HJ, McLean RR, Pugach O, Sima A, Moore-Clingenpeel M, Harrold LH. Longitudinal, regulatory-grade registry data can be used to emulate a target trial: an application on evaluating treatments for plaque psoriasis. ICPE, Washington, DC, August 22-26, 2025.

Singleton M, Pugach O, Chen W, McLean RR, Middaugh N, Litman HJ, Harrold LH. An alternative to non-responder imputation for study participants with missing outcomes in single-arm drug effectiveness studies: a case study in the PPD CorEvitas Psoriasis Registry. ICPE, Washington, DC, August 22-26, 2025.

Mansfield S, Singleton M, Moore-Clingenpeel M, Harrold LH, Litman HJ. Comparison of propensity score matching vs. inverse probability treatment weighting: a simulation study in the PPD CorEvitas Psoriasis Registry. ICPE, Washington, DC, August 22-26, 2025.

Strober B, Patel M, Bialik B, St John G, Garg V, Kang HK, Guo L, Singleton M, Beeghly A, Cotter D, Armstrong A. Incidence of psoriatic arthritis in biologic-naïve psoriasis patients achieving National Psoriasis Foundations's Treat to Target Goals: a real-world study using the CorEvitas Psoriasis Registry. EADV, Paris, France, September 17-20, 2025.

Strober B, Patel M, Bialik B, St John G, Garg V, Kang HK, Guo L, Singleton M, Beeghly A, Cotter D, Armstrong A. Incidence of psoriatic arthritis in biologic-naïve psoriasis patients achieving National Psoriasis Foundations's Treat to Target Goals: a real-world study using the CorEvitas Psoriasis Registry. SDPA, Washington, DC, June 25-29, 2025.

Strober B, Patel M, Bialik B, St John G, Garg V, Kang HK, Guo L, Singleton M, Beeghly A, Cotter D, Armstrong A. Incidence of psoriatic arthritis in biologic-naïve psoriasis patients achieving National Psoriasis Foundations's Treat to Target Goals: a real-world study using the CorEvitas Psoriasis Registry. Maui Derm NP+PA, Nashville, TN, September 20-23, 2025.

Strober B, Patel M, Bialik B, St John G, Garg V, Kang HK, Guo L, Singleton M, Beeghly A, Cotter D, Armstrong A. Incidence of psoriatic arthritis in biologic-naïve psoriasis patients achieving National Psoriasis Foundations's Treat to Target Goals: a real-world study using the CorEvitas Psoriasis Registry. SSDV Annual Congress, St. Gallen, Switzerland, September 3-5, 2025.

Strober B, Patel M, Bialik B, St John G, Garg V, Kang HK, Guo L, Singleton M, Beeghly A, Cotter D, Armstrong A. Incidence of psoriatic arthritis in biologic-naïve psoriasis patients achieving National Psoriasis Foundations's Treat to Target Goals: a real-world study using the CorEvitas Psoriasis Registry. DERM NP/PA CME Conference, Las Vegas, NV, July 23-26, 2025.

Armstrong AW, Ferris LK, Callis Duffin K, Sima AP, Eckmann T, Beeghly A, Bialik B, Patel M, Strober BE. Real-world skin clearance target achievement with persistent risankizumab use in patients with moderate-to-severe psoriasis from the PPD CorEvitas Psoriasis Registry. EADV Congress, Paris, France, September 17-20, 2025.

Strober B, Singleton M, Li AH, Dodge R, Chen W, Callahan K, Phillips M, Masurkar P, Herr H, Gomez B, Low R, Stark J. Real-world clinician- and patient-reported outcomes and treatment persistence following bimekizumab initiation in patients with psoriasis: 6-month results from the PPD CorEvitas Psoriasis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 23-26, 2025.

Armstrong AW, Lebwohl M, Srinivasan S, Zhuo J, Zhong Y, Gooderham M, Sima A, McLean RR, Papp KA, Merola JF, Gottlieb AB, Varga S, Strober B. Real-world comparative effectiveness of deucravacitinib vs apremilast at 6 months for plaque psoriasis: skin clearance outcomes from the RePhlect study. Fall Clinical Dermatology Conference, Las Vegas, NV, October 23-26, 2025.

Rheumatoid Arthritis

Harrold L, Wittstock K, Kelly S, Park S, Han X, Shan Y, Roberts-Toler C, Middaugh N, Khaychuk V. Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment With Abatacept, Stratified by Line of Therapy, in Patients With RA: Results From a Large, US, National Observational Study. ACR, Virtual, November 5-9, 2021. Poster

O'Brien J, Park SH, Blachley T, Marchese M, Middaugh N, Han X, Wittstock K, Harrold LR. Disparities in Burden of Disease in Patients With RA Across Racial and Ethnic Groups. ACR, Virtual, November 5-9, 2021. Poster

Pappas DA, Reed G, Kane K, Curtis JR, Kremer JM. Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients. ACR, Virtual, November 5-9, 2021. Poster

Sebba A, Bingham C, Bykerk V, Fiore S, Ford K, Janak JC, Pappas DA, Blachley T, Swapna D, Kremer JM, Yu M, Choy E. Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas' RA Registry. ACR, Virtual, November 5-9, 2021. Poster

Cohen SB, Shan Y, Litman HJ, McLean RR, Dandreo KJ, Gruben D, Germino R, Murray C, Kremer JM. Real-World Patterns of Methotrexate Withdrawal in Patients Receiving Tofacitinib: Results from the US Corrona RA Registry. AMCP, Virtual, April 12-16, 2021, EPoster

Padula A, Pappas DA, Fiore S, Blachley T, Ford K, Emeanuru K, Kremer JM. The Effect of Targeted Rheumatoid Arthritis Therapeutics on Systemic Inflammation and Anemia. Canadian Rheumatology Association (CRA), Virtual, February 24-26, 2021, Eposter

Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E, Solomon DH. Time- varying influence of rheumatoid arthritis disease activity on subsequent cardiovascular risks. OP0101, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.28

Dua A, Ford K, Fiore S, Pappas DA, Janak J, Blachley T, Emeanuru K, Kremer J, Kivitz A. Disease Activity and Patients-Reported Outcomes After Switching Between IL- 6 Receptor Inhibitors and JAK Inhibitors: An Analysis from the Corrona Registry. POS0606, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021- eular.1298

Curtis J, Fiore S, Ford K, Janak J, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk V. Meaningful Improvement and Worsening in Patients Who Do Not Achieve LDA and Switch Therapy to a New Biologic or Targeted Therapy: Results from the CORRONA Registry. POS0594, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.544.

Harrold L, Wittstock K, Kelly S, Park S, Han X, Shan Y, Roberts-Toler C, Middaugh N, Khaychuk V. Improvement in Clinical Disease Activity and Patient-Reported Outcomes after 6 Months of Treatment with Abatacept, Stratified by Line Of Therapy, in Patients with RA: Results from a large, US, National Observational Study. AB0202, June 2021 Volume 80 Supplement 1, doi.org/10.1136/annrheumdis-2021-eular.701

Kremer JM, Tundia N, McLean RR, Blachley T, Maniccia A, Pappas DA. Characteristics and six-month outcomes among real-world rheumatoid arthritis patients initiating upadacitinib: CorEvitas' Rheumatoid Arthritis Registry. POS0435, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021- eular.170

Reed G, Schrader A, Madsen A, Saunders, Litman H, Geier J. Methods and practical considerations in use of an external control to assess potential drug risk. ICPE 2021, Virtual, August 21-25, 2021. Eposter

Yoshida K, Guan H, Harrold LR, Solomon D. Potential direct effect of tumor- necrosis factor inhibitors on cardiovascular risk controlling for disease activity measure. SER, San Diego, CA, June 22-25, 2021. Poster

Galvao RW, Curtis JR, Harrold LR, Wu Q, Xie F, George MD. Accuracy of Administrative Claims Prescription Fill Data to Estimate Glucocorticoid Use and Dose in Patients with Rheumatoid Arthritis. ACR 2022, Philadelphia, PA, November 11-16, 2022. Ignite Talk and Virtual Poster

Aripova N, Reed G, England BR, Robinson WH, Pappas DA, Kremer JM, Thiele GM, Mikuls TR. An expanded anti-citrullinated protein antibody profile derived using unsupervised machine learning predicts treatment responses to biologic therapies in rheumatoid arthritis. ACR 2022, Philadelphia, PA, November 11-16, 2022. Oral Presentation

Baker J, Symons JM, Janak JC, Moore P, Kohl E, Gershenson B, Pugach O, Webb D, Martin AA, Saurigny D, Bracher M. Burden of Pain for RA Patients in the CorEvitas Rheumatoid Arthritis Registry. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster

Alotaibi M, Coras R, Pappas DA, Kremer JM, Mikuls T, Thiele G, Jain M, Guma M. Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster

Dua A, Ford K, Fiore S, Pappas DA, Janak J, Blachley T, Roberts-Toler C, Emeanuru K, Kremer J, Kivitz A. Disease Activity and Patients-Reported Outcomes After Switching Between IL-6 Receptor Inhibitors and JAK Inhibitors: An Analysis from the Corrona Registry. AWIR, Hilton Head, NC; August 18-21, 2022. Encore Poster

Dua A, Ford K, Fiore S, Pappas DA, Janak J, Blachley T, Roberts-Toler C, Emeanuru K, Kremer J, Kivitz A. Disease Activity and Patients-Reported Outcomes After Switching Between IL-6 Receptor Inhibitors and JAK Inhibitors: An Analysis from the Corrona Registry. CCR West 2022, October 20-23, 2022. Encore Poster

Dua A, Ford K, Fiore S, Pappas DA, Janak J, Blachley T, Roberts-Toler C, Emeanuru K, Kremer J, Kivitz A. Disease Activity and Patients-Reported Outcomes After Switching Between IL-6 Receptor Inhibitors and JAK Inhibitors: An Analysis from the Corrona Registry. RhAPP Congress 2022, Scottsdale, AZ, September 8-10, 2022. Encore Poster

Razmjou A, Wang JM, Shahbazian A, Curtis J, Pappas DA, Kremer J, Charles- Schoeman C. Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity. ACR 2022, Philadelphia, PA, November 11-16, 2022. Oral Presentation

Harrold LR, Zueger P, Nowell BW, Blachley T, Lakin PR, Curtis D, Stradford L, Venkatachalam S, Tundia N, Patel P. Early Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis Using Patient-Reported Outcomes Collected via Mobile Application. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster and Audio

Pappas D, Giles J, Reed G, Kane K, Curtis J, Kremer J. Effect of Biologic Agents on Lipid Levels and Cardiovascular Risk in Rheumatoid Arthritis Patients. ACR 2022, Philadelphia, PA, November 11-16, 2022. Ignite Talk and Virtual Poster

Hansen K, Mortezaei M, Nagy E, Wang C, Connell C, Radi Z, Litman H, Adami G, Rossini M. Impact of Tofacitinib on Fracture Risk in Rheumatoid Arthritis. ACR 2022, Philadelphia, PA, November 11-16, 2022. Virtual Poster

Pappas DA, O'Brien J, Kelleman M, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier D. Outcomes in Patients With Rheumatoid Arthritis Initiating Monotherapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors. ACR 2022, Philadelphia, PA, November 11-16, 2022. Poster

Pappas DA, O'Brien J, Guo L, Shan Y, Baker J, Kricorian G, Stryker S, Collier D. Outcomes in Patients With Rheumatoid Arthritis Initiating Therapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors. EULAR 2022, Copenhagen, Denmark, June 1-4, 2022. Poster

Pappas DA, O'Brien J, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier D. Outcomes of Etanercept and Janus Kinase Inhibitor Treatment After First-line Use of Adalimumab in Patients With Rheumatoid Arthritis. ACR 2022, Philadelphia, PA, November 11-16, 2022. Oral Presentation

Baker J, Symons JM, Janak JC, Pugach O, Kohl E, Yu M, Webb D, Martin AA, Saurigny D, Bracher M. Pain And Treatment Switching Among Patients In The CorEvitas™ Rheumatoid Arthritis Registry. ACR 2022, Philadelphia, PA, November 11-16, 2022. Oral Presentation

Pappas DA, Fiore S, Blachley T, Ford K, Emeanuru K, Kremer JM. The Effect of Targeted Rheumatoid Arthritis Therapeutics on Systemic Inflammation and Anemia. AWIR, Hilton Head, NC; August 18-21, 2022. Encore Poster

Pappas DA, Fiore S, Blachley T, Ford K, Emeanuru K, Kremer JM. The Effect of Targeted Rheumatoid Arthritis Therapeutics on Systemic Inflammation and Anemia. CCR West 2022, October 20-23, 2022. Encore Poster

Pappas DA, Fiore S, Blachley T, Ford K, Emeanuru K, Kremer JM. The Effect of Targeted Rheumatoid Arthritis Therapeutics on Systemic Inflammation and Anemia. RhAPP Congress 2022, Scottsdale, AZ, September 8-10, 2022. Encore Poster

Pala O, Pappas DA, Reed G, Kremer JM. The Impact of Disease Activity on Patient- Reported Cognitive Dysfunction in Rheumatoid Arthritis. ACR 2022, Philadelphia, PA, November 11-16, 2022. Ignite Talk and Virtual Poster

Loughlin AM, Sheffield KM, Pugach O, Shan M, Faries DE, Lakin P, Kerti S, Zhanglin C, Curtis S, Litman H, Harrold LR, Johnston JA. Using Bias Correction Methods with Hybrid Randomized Controlled Trial (RCT) Plus Real World (RW) Controls to Replicate Results of a Phase IIb RCT of Baricitinib for Rheumatoid Arthritis (RA). ICPE, Copenhagen, Denmark, August 24-28, 2022. Podium/Oral Presentation

Krueger WS, Harrold LR, Sima A, Eckmann T, Kilpatrick RD. Characteristics of first-line upadacitinib initiators and factors contributing to prescribing upadacitinib as first-line b/tsDMARD. EULAR 2023, May 31-June 3, 2023. AB0445

Pappas DA, O'Brien J, Kelleman M, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier D. Outcomes in Patients With Rheumatoid Arthritis Initiating Monotherapy With Etanercept, Adalimumab, or Janus Kinase Inhibitors. CCR East, Destin, FL, May 4-7, 2023.

Fukui S, Winkelmayr W, Tedeschi S, Marrugo J, Guan H, Harrold L, Litman H, Shinozaki, Solomon D. The relationship between disease activity of rheumatoid arthritis and kidney function. ACR Convergence, San Diego, CA, November 10-15, 2023.

Pugach O, Sheffield KM, Loughlin AM, Shan M, Faries D, Roberts-Toler C, Lakin P, Cui ZL, Harrold LR, Litman H. Evaluation of methods for building a hybrid real-world (RW) control arm for baricitinib phase IIB randomized controlled trial (RCT) in patients with rheumatoid arthritis (RA). ICPE, Halifax, NS, Canada, August 23-27, 2023

Osiri M, Niamane R, Sima A, O'Brien J, Dodge R, Levent Gunay M, Sweet LL, Shelbaya A, Rammaoui J. Tofacitinib use in rituximab-experienced RA patients. APLAR, Chiang Mai, Thailand, December 7-11, 2023.

Baker J, Mizelle K, Saikali W, Moore P, Kang H-J, Gruben D, Shelbaya A, Stockert L, O'Brien J. Characterization of second-line therapy after first Janus kinase inhibitor use: results from the CorEvitas RA Registry. ACR Convergence 2024, Washington, DC, November 14-19, 2024.

Paudel ML, Shadick N, Weinblatt M; Reed G, Litman H, Kremer JM, Pappas DA, Solomon DH. Development and external validation of a predictive model for progression to difficult-to-treat rheumatoid arthritis in biologic-experienced patients. EULAR, Barcelona, Spain, June 11-14, 2025.

Fukui S, Ørbo HS, Tedeschi SK, Guan H, Harrold LR, Litman HJ, Solomon DH. Effectiveness of biological and target-synthetic treatment in patients with rheumatoid arthritis and kidney dysfunction: a large prospective registry study. ACR, Washington, DC, May 3-5, 2025.

Litman HJ, Matsson A, Rao Y, Margolin ZR, Harrold LH, Johansson FD. Interpretable machine learning models: describing treatment patterns of healthcare providers selecting rheumatoid arthritis therapies to evaluate treatment policies. ICPE, Washington, DC, August 22-26, 2025.

RA Japan

Yamanaka H, Kishimoto M, Nishijima N, Yamashita K, Matsushima J, O'Brien J, Blachley T, Kerti SJ, Dave S, Tanaka Y. Baseline characteristics and outcomes of initiators of tocilizumab (TCZ) and other b/tsDMARDs in CorEvitas' RA Japan Registry. JCR 2022, Yokohama, Japan, April 25-27, 2022. Abstract and Oral Presentation

Reviews & Methods

McLean RR, Pugach O, Moore-Clingenpeel M, Sima AP, Harrold LH, Litman HJ. Beyond comparison: target trial emulation (TTE) principles strengthen observational single-arm (SA) effectiveness studies. ICPE, Washington, DC, August 22-26, 2025.

Moore-Clingenpeel M, Foster N, Harrold LH, Litman HJ. Review of ongoing PASS submitted to the HMA-EMA Catalogue of RWE Studies evaluating cancer as an outcome. ICPE, Washington, DC, August 22-26, 2025.

Austin AM, Foster N, Moore-Clingenpeel M, Harrold LH, Litman HJ. Comparison of performance of common exposure episode definitions in long-latency outcome studies. ICPE, Washington, DC, August 22-26, 2025.

Litman HJ, Henderson SC, Austin AM, Munoz Maldonado Y, McLean RR, Eliot M, Yu M, Main SI, Aleshire T, Bennett Mason DL, Harrold LH. Benefits of machine learning methods for identifying clinical features and patient characteristics associated with treatment outcomes in autoimmune conditions. ICPE, Washington, DC, August 22-26, 2025.

Chubb H, Foster N, Moore-Clingenpeel M, Rubin N, Cherry B, Barr C, Pappas D, Grace EL. Nuances of risk window selection for evaluation of acute adverse events. ICPE, Washington, DC, August 22-26, 2025.

